• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics expects FDA approval for next-gen 180-day CGM in ‘coming weeks’

January 5, 2022 By Sean Whooley

Eversense CGM Senseonics
The Eversense CGM [Image courtesy of Senseonics]
Senseonics (NYSE:SENS) announced that it anticipates the FDA to decide within weeks on approval of its new CGM system.

The company seeks a premarket approval supplement for the next-generation Eversense 180-day implantable continuous glucose monitoring (CGM) system. Data presented earlier this year demonstrated strong accuracy. The next-generation Eversense matched performance levels compared to the current 90-day sensor available in the U.S. — but with reduced calibration, down to one per day, with the duration extended to 180 days.

According to a news release, all queries raised during FDA review have been answered, with a decision over approval expected “in the coming weeks.”

“We understand that the FDA is at full capacity managing the backlog of COVID-19 related filings creating longer than expected review timelines,” Senseonics President & CEO Tim Goodnow said in the release. “We are confident a decision regarding approval of the 180-day system will be made in the coming weeks as the FDA continues to clear out the backlog.”

Senseonics also confirmed that it is designing plans with Ascensia Diabetes Care for a smooth transition to the 180-day system in the U.S., should it garner FDA approval. Those plans include marketing campaigns to promote the availability of system upgrades and engaging payors regarding reimbursement and coverage transitions.

The Germantown, Maryland-based company said the plans aim to minimize the impact to patients, providers and sales while taking into account the expected use of existing inventory in the first quarter of this year, with the transition to the new product earmarked for the second quarter of 2022. Additionally, Senseonics reiterated its 2021 financial outlook for full-year revenue to fall in the middle of its guidance range set between $12 million and $15 million.

“In 2021 we integrated operations and coordination activities with our commercial collaborator Ascensia Diabetes Care,” Goodnow said. “A thoughtful go-to-market strategy is being designed to target a smooth transition to the 180-day system while providing uninterrupted service for patients, providers and payors.

“We are excited to advance long-term solutions for people with diabetes as we continue to aim to make the new 180-day system available in the U.S..”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance Tagged With: FDA, Senseonics

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS